AU2008271307B2 - New use of known pharmacologically active chemical compounds - Google Patents

New use of known pharmacologically active chemical compounds Download PDF

Info

Publication number
AU2008271307B2
AU2008271307B2 AU2008271307A AU2008271307A AU2008271307B2 AU 2008271307 B2 AU2008271307 B2 AU 2008271307B2 AU 2008271307 A AU2008271307 A AU 2008271307A AU 2008271307 A AU2008271307 A AU 2008271307A AU 2008271307 B2 AU2008271307 B2 AU 2008271307B2
Authority
AU
Australia
Prior art keywords
alpha
pharmaceutically acceptable
subject
acid
akg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008271307A
Other languages
English (en)
Other versions
AU2008271307A1 (en
Inventor
Stefan G. Pierzynowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Protista Biotechnology AB
Original Assignee
Protista Biotechnology AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protista Biotechnology AB filed Critical Protista Biotechnology AB
Publication of AU2008271307A1 publication Critical patent/AU2008271307A1/en
Application granted granted Critical
Publication of AU2008271307B2 publication Critical patent/AU2008271307B2/en
Assigned to PROTISTA BIOTECHNOLOGY AB reassignment PROTISTA BIOTECHNOLOGY AB Request for Assignment Assignors: ENTRESS AB
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2008271307A 2007-07-02 2008-06-27 New use of known pharmacologically active chemical compounds Ceased AU2008271307B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0701602 2007-07-02
SE0701602-5 2007-07-02
PCT/SE2008/050797 WO2009005464A1 (en) 2007-07-02 2008-06-27 New use of known pharmacologically active chemical compounds

Publications (2)

Publication Number Publication Date
AU2008271307A1 AU2008271307A1 (en) 2009-01-08
AU2008271307B2 true AU2008271307B2 (en) 2013-10-24

Family

ID=40226336

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008271307A Ceased AU2008271307B2 (en) 2007-07-02 2008-06-27 New use of known pharmacologically active chemical compounds

Country Status (11)

Country Link
US (1) US20110039935A1 (enExample)
EP (1) EP2173336B1 (enExample)
JP (1) JP5735274B2 (enExample)
KR (1) KR20100039874A (enExample)
CN (1) CN101730532B (enExample)
AU (1) AU2008271307B2 (enExample)
BR (1) BRPI0814184A2 (enExample)
CA (1) CA2691746C (enExample)
EA (1) EA018554B1 (enExample)
MX (1) MX2009013937A (enExample)
WO (1) WO2009005464A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123229A1 (en) 2014-02-12 2015-08-20 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms
US10278185B2 (en) 2014-03-20 2019-04-30 Huawei Device (Dongguan) Co., Ltd. Signal sending method, user equipment, and base station
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
CA3142781A1 (en) * 2019-06-10 2020-12-17 Buck Institute For Research On Aging Methods and compositions for altering senescence associated secretory phenotype
WO2021262298A1 (en) * 2020-06-23 2021-12-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic compounds and electrophilic prodrugs for treating aneurysm
CN117530940A (zh) * 2023-10-11 2024-02-09 四川大学华西第二医院 α-酮戊二酸在制备促髓鞘修复、改善神经炎症的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046880A1 (en) * 2004-10-29 2006-05-04 Sgp & Sons Ab Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402027D0 (sv) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
JP2000093096A (ja) * 1998-09-21 2000-04-04 Snow Brand Milk Prod Co Ltd ゼリー状食品
DE19929993C2 (de) * 1999-06-30 2001-07-05 Sueddeutsche Kalkstickstoff Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung
CN1203168C (zh) * 2001-08-17 2005-05-25 杨志东 一种制备食疗保健醋的方法及用该方法生产的食疗保健醋
US20040220265A1 (en) * 2002-07-25 2004-11-04 Celluar Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US7194301B2 (en) * 2003-10-06 2007-03-20 Transneuronic, Inc. Method for screening and treating patients at risk of medical disorders
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
WO2007002365A2 (en) * 2005-06-24 2007-01-04 Albert Einstein College Of Medicine Of Yeshiva University Modulation of amino acid metabolism in the hypothalamus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006046880A1 (en) * 2004-10-29 2006-05-04 Sgp & Sons Ab Nutritional and/or pharmaceutical preparation for use in prophylaxis and treatment of disturbances in microelements absorption from the alimentary canal

Also Published As

Publication number Publication date
JP5735274B2 (ja) 2015-06-17
EP2173336B1 (en) 2016-03-30
EA018554B1 (ru) 2013-08-30
CN101730532B (zh) 2012-05-30
BRPI0814184A2 (pt) 2015-03-03
EA201070084A1 (ru) 2010-10-29
JP2010532348A (ja) 2010-10-07
AU2008271307A1 (en) 2009-01-08
KR20100039874A (ko) 2010-04-16
CN101730532A (zh) 2010-06-09
EP2173336A4 (en) 2010-11-10
HK1140423A1 (en) 2010-10-15
US20110039935A1 (en) 2011-02-17
CA2691746A1 (en) 2009-01-08
EP2173336A1 (en) 2010-04-14
WO2009005464A1 (en) 2009-01-08
MX2009013937A (es) 2010-04-30
CA2691746C (en) 2016-02-02

Similar Documents

Publication Publication Date Title
CA2691746C (en) Use of alpha-ketoglutarate in the treatment of hypertension
ES2219868T3 (es) Agentes anti-estres y alimentos funcionales.
US6638542B2 (en) Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
Bennett et al. Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine
Casanova-Marti et al. Antihyperglycemic effect of a chicken feet hydrolysate via the incretin system: DPP-IV-inhibitory activity and GLP-1 release stimulation
WO2007082914A2 (en) Method of diagnosis and method of treatment
Chaitow Amino acids in therapy: a guide to the therapeutic application of protein constituents
US20100166796A1 (en) Method of increasing cellular function and health of glutathione deficient animals
US20200345677A1 (en) Composition for preventing or improving nociceptive pain
KR101212583B1 (ko) 혈장 지질을 낮추기 위한 알파 케토글루타레이트 및 관련화합물의 용도
Goldberg et al. Influence of inhibitors of prostaglandin synthesis on venoconstrictor responses to bradykinin.
CA2664982C (en) Cleavable carnitine compound
KR100304312B1 (ko) 아연이보충된전립선추출물
Kouguchi et al. Vasoprotective effect of foods as treatments: chicken collagen hydrolysate
Fatima et al. Nutraceutical and Nanonutraceutical in the Management of CVD and Hypertension
US11389417B2 (en) Active ingredient consisting of a mixture of polylysine compounds and use in the prevention of strokes and the treatment of the post-stroke inflammatory phase
HK1140423B (en) Use of known pharmacologically active chemical compounds
RU2454999C2 (ru) Лекарственное средство, применяющееся при поражениях хряща
Martínez et al. Blunted non-nitric oxide vasodilatory neurotransmission in penile arteries from renal hypertensive rats
JP2002145767A (ja) 循環器疾患治療剤および健康食品
GB2600668A (en) Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection.
US20080124449A1 (en) Food for Preventing Life Style-Related Diseases
Pathera et al. Health promoting functional properties of meat and meat products
MXPA04010692A (es) Composicion para el tratamiento de la obesidad e hiperlipidemia.
KR100637415B1 (ko) Ａｃｅ 억제활성을 갖는 폴리펩타이드들을 유효성분으로함유하는 고혈압의 예방 및 치료용 조성물

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: PROTISTA BIOTECHNOLOGY AB

Free format text: FORMER APPLICANT(S): ENTRESS AB

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired